HER-2 / ErbB2 Antibody (3B5)

HER-2 / ErbB2 Monoclonal Antibody for Western blot, IF, ICC, IHC, IP

>> See 49 other antibodies for ERBB2 (Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, MLN 19, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, CD340, MLN19, NEU, NGL, c-erb B2/neu protein, herstatin, metas)
Synonyms:
Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, MLN 19, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, CD340, MLN19, NEU, NGL, c-erb B2/neu protein, herstatin, metas
Entrez Gene ID:
UniProt ID:
Details
Host / Isotype: Mouse / IgG1
Class: Monoclonal
Type: Antibody
Clone: 3B5
Tested Species Reactivity: Human (Hu), Mouse (Ms), Rat (Rt), Non-human primate (Nhp)
Published Species Reactivity: Avian (Av), Human (Hu), Mouse (Ms), Rat (Rt)
Immunogen: A synthetic peptide from the C-terminus of human c-erbB-2 protein. This Sequence Is Identical In Rat Neu Protein.
Ordering Information
Pierce HER-2 / ErbB2 Antibody (3B5)
Product #
MA5-13675
Size
500 ul
Price
$320.00
Purchase
Add HER-2 / ErbB2 Antibody (3B5) to your cart.
Tested Applications Dilution *
Western Blot (WB) 0.5-1.0 µg/ml
Immunofluorescence (IF) 1:50-1:500
Immunocytochemistry (ICC) 1:50-1:500
Immunohistochemistry (IHC) 1:1000-1:1500
Immunoprecipitation (IP) 2µg/mg protein lysate
Published Applications Dilution
Western Blot (WB) See publications below
Immunocytochemistry (ICC) See publications below
Immunohistochemistry (IHC) See publications below
Flow Cytometry (FACS) See publications below
Immunoprecipitation (IP) See publications below
ELISA (ELISA) See publications below
* Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.
Form Information
Form: Liquid
Concentration: 0.2mg/ml
Purification: Protein G
Storage Buffer: PBS, pH 7.4, with 0.2% BSA
Preservative: 0.09% sodium azide
Storage Conditions: 4° C
Product Specific Information
MA5-13675 targets HER-2 in IHC, IP, ICC, IF and WB applications and shows reactivity with Human, mouse, Non-human primate, and Rat samples.

The MA5-13675 immunogen is a synthetic peptide from the C-terminus of human c-erbB-2 protein. This Sequence Is Identical In Rat Neu Protein.
General Information
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
Product Images
  • HER-2 / ErbB2 Antibody (MA5-13675) in WB
    MA5-13675_WesternBlot.jpg

    Western Blot with anti-HER-2 / ErbB2 Monoclonal Antibody [3B5] (MA5-13675) (MA5-13675_WesternBlot.jpg)

    Western Blot with anti-HER-2 / ErbB2 Monoclonal Antibody [3B5] (MA5-13675)

    Western blot of HER-2 using HER-2 Monoclonal Antibody (MA5-13675) on SKBR3 Cells and MAD109 Cells.
  • HER-2 / ErbB2 Antibody (MA5-13675) in IF
    MA5-13675-IF-SK-BR-3_20141010134052.jpg

    Immunofluorescence with anti-HER-2 / ErbB2 Monoclonal Antibody [3B5] (MA5-13675) (MA5-13675-IF-SK-BR-3_20141010134052.jpg)

    Immunofluorescence with anti-HER-2 / ErbB2 Monoclonal Antibody [3B5] (MA5-13675)

    Immunofluorescent analysis of HER-2/ErbB2 (green) showing membrane staining in SK-BR-3 cells (right) compared to a negative control without primary antibody (left). Cells were was permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a HER-2/ErbB2 monoclonal antibody (Product # MA5-13675) in 3% BSA-PBS at a dilution of 1:100 and incubated overnight at 4ºC in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-488 conjugated secondary antibody in PBS at room temperature in the dark. Nuclei were stained with DAPI (blue) and images were taken at a magnification of 60x.
  • HER-2 / ErbB2 Antibody (MA5-13675) in IP
    MA5-13675_Immunoprecipitation.jpg

    Immunoprecipitation with anti-HER-2 / ErbB2 Monoclonal Antibody [3B5] (MA5-13675) (MA5-13675_Immunoprecipitation.jpg)

    Immunoprecipitation with anti-HER-2 / ErbB2 Monoclonal Antibody [3B5] (MA5-13675)

    Immunoprecipitation of HER-2 using HER-2 Monoclonal Antibody (MA5-13675) on denatured Human SKBR3 Cells.
  • HER-2 / ErbB2 Antibody (MA5-13675) in IP
    MA5-13675_Immunoprecipitation_1.jpg

    Immunoprecipitation with anti-HER-2 / ErbB2 Monoclonal Antibody [3B5] (MA5-13675) (MA5-13675_Immunoprecipitation_1.jpg)

    Immunoprecipitation with anti-HER-2 / ErbB2 Monoclonal Antibody [3B5] (MA5-13675)

    Immunoprecipitation of HER-2 using HER-2 Monoclonal Antibody (MA5-13675) on Native Human SKBR3 Cells.
Publications:
Western Blot
  Species / Dilution Summary
  Hu / 0.2 ug/ml
MA5-13675 was used in western blot to study the role of p38 MAP kinase in the induction of apoptosis in androgen-independent prostate cancer cells by the EGFR inhibitor typhostin AG825

Cancer Res. 2001 Oct 15;61(20):7408-12.
"Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2."
Author(s): Murillo H, Schmidt LJ, Tindall DJ
Number of Citations: 8
(See PubMed article )
  Hu / 1:1000
MA5-13675 was used in western blot to study the immune response to EC HER-2/NEU peptides not shared by the host's proteome

Int J Cancer. 2002 Apr 10;98(5):741-7.
"Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome."
Author(s): Mittelman A, Lucchese A, Sinha AA, Kanduc D
Number of Citations: 5
(See PubMed article )
  Hu / 1:400
MA5-13675 was used in western blot to study whether it is possible to predict which peptides will evoke a humoral immune response using the human HER-2/neu breast cancer-associated antigen as a model

Peptides. 2003 Feb;24(2):193-7.
"Role of MHC II affinity and molecular mimicry in defining anti-HER-2/neu MAb-3 linear peptide epitope."
Author(s): Lucchese A, Stevanovic S, Sinha AA, Mittelman A, Kanduc D
Number of Citations: 0
(See PubMed article )
  Hu / 1:400
MA5-13675 was used in immunocytochemistry, immunohistochemistry, and western blot to characterize HER2 in human tumors and cell lines

Int J Cancer. 2004 Feb 10;108(4):540-8.
"HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors."
Author(s): Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA
Number of Citations: 1
(See PubMed article )
  Hu / 1:200
MA5-13675 was used in western blot to study the effects of vitamin D receptor agonists on androgen-dependent LNCaP human prostate cancer cell growth

J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):37-46.
"Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells."
Author(s): Stewart LV, Lyles B, Lin MF, Weigel NL
Number of Citations: 3
(See PubMed article )
  Hu / 1:400
MA5-13675 was used in western blot to examine the effect of anti-EGFR and ErbB-2 antibodies on the survival of human colon cancer cells

Cancer Lett. 2007 Jun 28;251(2):237-46.
"Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells."
Author(s): Half E, Sun Y, Sinicrope FA
Number of Citations: 1
(See PubMed article )
  Hu / 0
MA5-13675 was used in western blot to investigate the impact of epidermal growth factor on neuroendocrine differentiation of LNCaP cells

Neoplasia. 2007 Aug;9(8):614-24.
"EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt."
Author(s): Martín-Orozco RM, Almaraz-Pro C, Rodríguez-Ubreva FJ, Cortés MA, Ropero S, Colomer R, López-Ruiz P, Colás B
Number of Citations: 7
(See PubMed article )
  Hu / Not Cited
MA5-13675 was used in western blot to develop a cell-based screening system to identify compounds that inhibit influenza A viral RNA transcription/replication

Sci Rep. 2013;3():1106.
"A cell-based screening system for influenza A viral RNA transcription/replication inhibitors."
Author(s): Ozawa M, Shimojima M, Goto H, Watanabe S, Hatta Y, Kiso M, Furuta Y, Horimoto T, Peters NR, Hoffmann FM, Kawaoka Y
Number of Citations: 0
(See PubMed article )
  Hu / 1:500
MA5-13675 was used in western blot to study the pharmacodynamics of afatinib in HER2-positive gastric cancer using PET

J Nucl Med. 2013 Jun;54(6):936-43.
"Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET."
Author(s): Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS
Number of Citations: 4
(See PubMed article )
  Ms / 1:1000
MA5-13675 was used in western blot to study the efficacy of gene targeting of ErbB3 using an in vivo recombination unidirectional DNA inversion technology

Genesis. 2006 Oct;44(10):477-86.
"Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy."
Author(s): Qu S, Rinehart C, Wu HH, Wang SE, Carter B, Xin H, Kotlikoff M, Arteaga CL
Number of Citations: 10
(See PubMed article )
  Ms / Not Cited
MA5-13675 was used in immunoprecipitation and western blot to study the use of an antibody-cytotoxic drug conjugate to target HER2-positive breast cancer

Cancer Res. 2008 Nov 15;68(22):9280-90.
"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate."
Author(s): Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX
Number of Citations: 83
(See PubMed article )
  Ms / Not Cited
MA5-13675 was used in immunoprecipitation and western blot to study the mechanism by which HSP90 inhibitors suppress growth in Trastuzumab-resistant tumors

Oncogene. 2010 Jan 21;29(3):325-34.
"Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth."
Author(s): Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, Norton L, Solit DB, Arribas J, Baselga J, Rosen N
Number of Citations: 25
(See PubMed article )
  Ms / Not Cited
MA5-13675 was used in western blot to profile protein expression in primary mammary epithelial cells derived from MMTV-neu mice to identify novel biomarkers of tumorigenesis

IUBMB Life. 2010 Jan;62(1):41-50.
"Protein expression profiling of primary mammary epithelial cells derived from MMTV-neu mice revealed that HER2/NEU-driven changes in protein expression are functionally clustered."
Author(s): Park S, Lee KM, Ju JH, Kim J, Noh DY, Lee T, Shin I
Number of Citations: 0
(See PubMed article )
  Ms / 1:1000
MA5-13675 was used in western blot to study the role of BRCA-1 in the protective effects of prepubertal genistein against mammary tumorigenesis

Cancer Prev Res (Phila). 2011 Sep;4(9):1436-48.
"Protective effects of prepubertal genistein exposure on mammary tumorigenesis are dependent on BRCA1 expression."
Author(s): de Assis S, Warri A, Benitez C, Helferich W, Hilakivi-Clarke L
Number of Citations: 0
(See PubMed article )
Immunocytochemistry
  Species / Dilution Summary
  Hu / Not Cited
MA5-13675 was used in immunocytochemistry, immunohistochemistry, and western blot to characterize HER2 in human tumors and cell lines

Int J Cancer. 2004 Feb 10;108(4):540-8.
"HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors."
Author(s): Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA
Number of Citations: 1
(See PubMed article )
  Hu / 1:200
MA5-13675 was used in immunocytochemistry to investigate the mechanism for the malignant rhabdoid tumor treatment with trastuzumab

Clin Cancer Res. 2008 Feb 15;14(4):1192-9.
"Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity."
Author(s): Katsumi Y, Kuwahara Y, Tamura S, Kikuchi K, Otabe O, Tsuchiya K, Iehara T, Kuroda H, Hosoi H, Sugimoto T
Number of Citations: 1
(See PubMed article )
  Rt / Not Cited
MA5-13675 was used in immunocytochemistry to study the mechanisms by which glioma cells evade the actions of cytolytic effector lymphocytes

J Immunol. 2010 Oct 15;185(8):4793-803.
"Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytes."
Author(s): Hoa N, Ge L, Kuznetsov Y, McPherson A, Cornforth AN, Pham JT, Myers MP, Ahmed N, Salsman VS, Lamb LS Jr, Bowersock JE, Hu Y, Zhou YH, Jadus MR
Number of Citations: 5
(See PubMed article )
Immunohistochemistry
  Species / Dilution Summary
  Av / 1 ug/ml
MA5-13675 was used in immunohistochemistry to investigate the similar changes of p53, ras, and HER-2/neu genes in ovatian adenocarcinomas between chicken and human

Cancer Prev Res (Phila). 2009 Feb;2(2):114-21.
"Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu."
Author(s): Hakim AA, Barry CP, Barnes HJ, Anderson KE, Petitte J, Whitaker R, Lancaster JM, Wenham RM, Carver DK, Turbov J, Berchuck A, Kopelovich L, Rodriguez GC
Number of Citations: 1
(See PubMed article )
  Hu / 1:10000
MA5-13675 was used in immunohistochemistry to study whether refining the grading of low-grade neuroendocrine tumors of the midgut and unknown origin is of prognostic/predictive value

Hum Pathol. 2002 Nov;33(11):1126-32.
"Classification of low-grade neuroendocrine tumors of midgut and unknown origin."
Author(s): Van Eeden S, Quaedvlieg PF, Taal BG, Offerhaus GJ, Lamers CB, Van Velthuysen ML
Number of Citations: 12
(See PubMed article )
  Hu / Not Cited
MA5-13675 was used in immunohistochemistry to study whether early assessment of apoptosis following breast cancer neoadjuvant chemotherapy predicts clinical response

Clin Cancer Res. 2003 Mar;9(3):955-60.
"Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response."
Author(s): Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ
Number of Citations: 8
(See PubMed article )
  Hu / Not Cited
MA5-13675 was used in immunohistochemistry to study the histopathology and immunohistochemistry of breast carcinoma in pregnant women

Cancer. 2003 Sep 1;98(5):1055-60.
"Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features."
Author(s): Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A
Number of Citations: 16
(See PubMed article )
  Hu / 1:200
MA5-13675 was used in immunocytochemistry, immunohistochemistry, and western blot to characterize HER2 in human tumors and cell lines

Int J Cancer. 2004 Feb 10;108(4):540-8.
"HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors."
Author(s): Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA
Number of Citations: 1
(See PubMed article )
  Hu / 1:2000
MA5-13675 was used in immunohistochemistry to report the clinical cases of cystic hypersecretory carcinoma

Histopathology. 2005 Jan;46(1):43-9.
"Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases."
Author(s): Skalova A, Ryska A, Kajo K, Di Palma S, Kinkor Z, Michal M
Number of Citations: 1
(See PubMed article )
  Hu / 1:2000
MA5-13675 was used in immunohistochemistry to characterize non-invasive carcinoma ex pleomorphic adenoma through HER-2/neu and MIB1 expression

Histopathology. 2005 Feb;46(2):144-52.
"Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry."
Author(s): Di Palma S, Skálová A, Vanìèek T, Simpson RH, Stárek I, Leivo I
Number of Citations: 4
(See PubMed article )
  Hu / 1:2000
MA5-13675 was used in immunohistochemistry to investigate clonality of sclerosing polycystic adenosis by human androgen receptor polymorphism

Am J Surg Pathol. 2006 Aug;30(8):939-44.
"Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker."
Author(s): Skálová A, Gnepp DR, Simpson RH, Lewis JE, Janssen D, Sima R, Vanecek T, Di Palma S, Michal M
Number of Citations: 2
(See PubMed article )
  Hu / 0
MA5-13675 was used in immunohistochemistry to study breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation

J Clin Oncol. 2007 Jan 1;25(1):64-9.
"Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation."
Author(s): Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van't Veer LJ
Number of Citations: 14
(See PubMed article )
  Hu / 1:100
MA5-13675 was used in immunohistochemistry to study the value of serum HER-2 receptor extracellular domain measurements for predicting the response to chemotherapy in primary breast cancer patients

Cancer. 2007 Feb 1;109(3):496-501.
"Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy."
Author(s): Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M
Number of Citations: 11
(See PubMed article )
  Hu / 1:3000
MA5-13675 was used in immunohistochemistry to study triple negative breast carcinoma histopathology and gene expression patterns in order to define clinically significant sub-groups

Breast Cancer Res. 2007;9(5):R65.
"Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas."
Author(s): Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ
Number of Citations: 108
(See PubMed article )
  Hu / 1:250
MA5-13675 was used in immunohistochemistry to report on a case of primary neuroendocrine carcinoma of the breast

Tumori. 2007 Sep-Oct;93(5):496-8.
"Primary neuroendocrine carcinoma of the breast: a case report."
Author(s): Yaren A, Kelten C, Akbulut M, Teke Z, Duzcan E, Erdem E
Number of Citations: 1
(See PubMed article )
  Hu / 0
MA5-13675 was used in flow cytometry and immunohistochemistry to develop a co-culture model from an invasive lobular carcinoma for the evaluation of therapeutic agents

BMC Cancer. 2008 Apr 24;8():119.
"A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents."
Author(s): Piechocki MP
Number of Citations: 0
(See PubMed article )
  Hu / 1:1
MA5-13675 was used in immunohistochemistry to identify biomarkers that predict the recurrence of benign meningiomas

Br J Neurosurg. 2011 Dec;25(6):707-13.
"Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression."
Author(s): Abdelzaher E, El-Gendi SM, Yehya A, Gowil AG
Number of Citations: 1
(See PubMed article )
  Hu / 1:200
MA5-13675 was used in immunohistochemistry to study the prognostic value of stromal caveolin-1 in breast cancer

Pathol Oncol Res. 2012 Apr;18(2):459-69.
"Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome."
Author(s): El-Gendi SM, Mostafa MF, El-Gendi AM
Number of Citations: 4
(See PubMed article )
  Hu / 1:400
MA5-13675 was used in immunohistochemistry to study six cases of mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation

Pathol Res Pract. 2012 Mar 15;208(3):147-50.
"Clinicopathologic features of the mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation in a subset of six cases."
Author(s): Yigit S, Pehlivan FS, Evcim G, Etit D
Number of Citations: 0
(See PubMed article )
  Ms / 1:70
MA5-13675 was used in immunohistochemistry to study the effect of vitamin D receptor gene dosage on mammary gland morphology and tumorigenesis

Carcinogenesis. 2004 Dec;25(12):2361-72.
"Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice."
Author(s): Zinser GM, Welsh J
Number of Citations: 8
(See PubMed article )
Flow Cytometry
  Species / Dilution Summary
  Ms / 0
MA5-13675 was used in flow cytometry and immunohistochemistry to develop a co-culture model from an invasive lobular carcinoma for the evaluation of therapeutic agents

BMC Cancer. 2008 Apr 24;8():119.
"A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents."
Author(s): Piechocki MP
Number of Citations: 0
(See PubMed article )
Immunoprecipitation
  Species / Dilution Summary
  Hu / Not Cited
MA5-13675 was used in immunoprecipitation and western blot to study the use of an antibody-cytotoxic drug conjugate to target HER2-positive breast cancer

Cancer Res. 2008 Nov 15;68(22):9280-90.
"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate."
Author(s): Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX
Number of Citations: 83
(See PubMed article )
  Hu / Not Cited
MA5-13675 was used in immunoprecipitation to investigate the state of HER1-HER2 interaction and modification in cell lines and tumors

Breast Cancer Res. 2011 Apr 15;13(2):R44.
"Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action."
Author(s): DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J
Number of Citations: 1
(See PubMed article )
  Ms / Not Cited
MA5-13675 was used in immunoprecipitation to study three novel mouse mammary tumor cell lines for use in TGF-beta and Neu pathway signaling studies

Breast Cancer Res. 2004;6(5):R514-30.
"Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition."
Author(s): Lenferink AE, Magoon J, Cantin C, O'Connor-McCourt MD
Number of Citations: 3
(See PubMed article )
  Ms / Not Cited
MA5-13675 was used in immunoprecipitation and western blot to study the mechanism by which HSP90 inhibitors suppress growth in Trastuzumab-resistant tumors

Oncogene. 2010 Jan 21;29(3):325-34.
"Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth."
Author(s): Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, Norton L, Solit DB, Arribas J, Baselga J, Rosen N
Number of Citations: 25
(See PubMed article )
ELISA
  Species / Dilution Summary
  Hu / Not Cited
MA5-13675 was used in ELISA to study the receptor tyrosine kinase activation by through antibody microarrays

Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9330-5.
"Profiling receptor tyrosine kinase activation by using Ab microarrays."
Author(s): Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK
Number of Citations: 1
(See PubMed article )
(This product is for In Vitro experimental use only. Not for resale without express authorization.)
Part of Thermo Fisher Scientific